Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

THOUSAND OAKS, Calif., June 1, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting at 4:00 p.m.

Amgen to Webcast Investor Meeting at ASCO 2021

Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.

Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment

Amgen Inc (NASDAQ: AMGN) and Kyowa Kirin Co Ltd (OTC: KYKOF) have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-OX40 fully human monoclonal antibody in development for atopic dermatitis, with potential in other autoimmune diseases. In February, Kyowa Kirin announced positive results from a Phase 2 study of KHK4083 in patients with moderate-to-severe atopic dermatitis.

Amgen, Kyowa Kirin Ink $1.25B Deal for Developing KHK4083 In Skin Disorders

Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Several Other Inflammatory Diseases Moderate-to-Severe Atopic Dermatitis Affects Nearly 30 Million People in Major Global Markets1 Amgen to Host Investor Call at 8:00 a.m. EST THOUSAND OAKS, Calif.

Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.

Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer

THOUSAND OAKS, Calif., May 28, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m.

Amgen To Present At The 2021 Jefferies Healthcare Conference

Amgen's newest cancer drug is the first KRAS inhibitor class to gain approval, after decades of trying by other drug developers. Mirati hopes to follow fast.

This Just-Approved Amgen Drug Is the First to Hit a Hard Target in Cancer

Cowen expects the drug to sell $1 billion annually by 2026.

Amgen Wins FDA Drug Approval For Lung Cancer With Mutation Formerly Resistant To Therapy

The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras mutation. The approval covers the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy.

Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer

Shares of Amgen were up 0.5% in trading on Friday after the Food and Drug Administration said it approved Amgen's Lumakras, a new therapy for adults with a certain type of non-small cell lung cancer. Before patients qualify for treatment, they have to test positive for the KRAS G12C mutation and have previously undergone treatment.

Amgen gets FDA approval for new lung-cancer drug

THOUSAND OAKS, Calif., May 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Amgen is a wide moat biotechnology company with a well-diversified stable of drugs. The recent drop presents a buying opportunity. It should see a strong rebound in the second quarter, and the recent Five Prime Therapeutics acquisition could be a meaningful growth driver.

Amgen: Your Buy-The-Drop Opportunity Is Knocking

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Why Is Amgen (AMGN) Up 0.8% Since Last Earnings Report?

Apple

PayPal

When you have to grow your own nest egg, a balance among growth, reliability, and longevity must be found.

3 Stocks for a Better Retirement

Cisco Systems

You won't be paying much of a premium for either of these dividend stocks.

2 Great Income Stocks to Buy Right Now

Bristol-Myers

General Dynamics

Lockheed Martin

Merck

Pfizer

7 High-Quality Dividend Growth Stocks Trading Below Fair Value

Accenture Plc

Best Buy

HCA Healthcare

JPMorgan Chase & Co

Lennar

Nucor

Omnicom Group

Target

Excess free cash flow can often be used to generate long-term value for companies. Here are 10 FCF stocks that could be poised for growth.

10 Free Cash Flow Gushers for Dividends, Buybacks and More

Colgate-Palmolive

McDonald's

We're reiterating three long ideas that recently reported calendar 1Q21 earnings. Amgen's pipeline provides a long runway for plenty of growth, though it's priced for permanent profit decline.

Q1 Earnings Reveal Plenty Of Upside In Amgen, McDonald's And Colgate-Palmolive

AbbVie

Here's why you should consider buying into these two companies for the long run.

2 Healthcare Stocks Perfect to Buy Now and Hold Until Retirement

THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m.

Amgen To Present AT the Cowen 2nd Annual Virtual Oncology Innovation Summit

THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4-8, 2021.

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021

I'm reiterating three Long Ideas that have underperformed the S&P 500 since my original reports: Amgen, Inc (AMGN), McDonald's Corporation (MCD), and Colgate-Palmolive Company (CL).

1Q21 Earnings Reveal Plenty Of Upside In Amgen, McDonald's And Colgate-Palmolive

Novartis

The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG's (NYSE: NVS) Sandoz from selling a biosimilar of the drug in the U.S. until 2029. The justices turned away Novartis subsidiary Sandoz Inc's appeal of a lower court decision that upheld the validity of the patents.

Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report

THOUSAND OAKS, Calif., May 13, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal NAVIGATOR Phase 3 trial demonstrating superiority across every primary and key secondary endpoint in a broad population of severe asthma patients, compared to placebo when added to standard of care (SoC).

New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients

THOUSAND OAKS, Calif., May 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab) open label extension trial of patients living with HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events, including complex revascularization procedures.

News for Amgen Stock (AMGN)